PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
PTC Therapeutics (PTCT) Q3 Revenues Beat
October 28, 2021 4:01 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.89), $0.49 worse than the analyst estimate of ($1.40). Revenue for the quarter came in at $138.7 million versus the consensus estimate of $126.44 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More